A Phase 4 interventional study of Arformoterol Tartrate Inhalation Solution and Tiotropium in Chronic Obstructive Pulmonary Disease, Bronchitis and Emphysema, sponsored by Sumitomo Pharma America, Inc.. Completed at 28 sites in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-06-04.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 39th largest by enrollment, is one of 8 that started in 2006, is one of 26 in phase 4, and was the 17th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 235 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 24 finished, 15 (63%) have results posted.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., this one is the 12th largest by enrollment, is the only one that started in 2006, is one of 5 in phase 4, and was the 4th registered.
Sumitomo Pharma Co., Ltd.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2001.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 24 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).
This study is a multicenter, randomized, modified-blind, double-dummy two-week parallel-group efficacy and safety study of arformoterol tartrate inhalation solution twice daily, tiotropium inhalation powder once daily and arformoterol tartrate inhalation solution twice daily and tiotropium inhalation powder once daily (dosed sequentially) in subjects with COPD. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
Drug: Arformoterol Tartrate Inhalation Solution · Drug: Placebo
Tiotropium 18 mcg once daily/Placebo Inhalation Solution
Drug: Tiotropium · Drug: Placebo
Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily
Drug: Arformoterol and Tiotropium
Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
Also known as: Brovana®
Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
Also known as: Spiriva
Drug pages: Formoterol · Tiotropium
Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
Also known as: Brovana, Spiriva
Placebo inhalation solution and placebo inhalation powder
Time-normalized Area Under the Change From Study Baseline Curve for Forced Expiratory Volume in One Second (FEV1) Over 24 Hours (nAUC0-24B)
Time frame: 24 hours following two weeks of dosing.
Time-normalized Area From Study Baseline Curve for FEV1 Over 0-12 Hours (nAUC0-12B)
Time frame: 0-12 hours following two weeks of dosing
Time Normalized Area Under the Change From Study Baseline Curve for FEV1 Over 12-24 Hours (nAUC12-24B)
Time frame: Following 2 weeks of dosing
Change in FEV1 From Study Baseline to the 24-hour Timepoint (Trough)
Trough FEV1 is defined as the measurement collected approximately 24 hours after the first in-clinic double-blind dose at Week 0. Change is calculated as Week 2 24 hour post first dose FEV1 - Week 0 pre-first dose FEV1.
Time frame: Following 2 weeks of dosing
Change in FEV1 From Study Baseline at Each Assessed Timepoint Post First Dose of Study Medication
Baseline is FEV1 measurement collected prior to the first double-blind dose at week 0. Change defined as Week 0 FEV1 - Week 2 pre first dose FEV1.
Time frame: 2 weeks
Change in FEV1 Percent of Predicted From Study Baseline at Each Assessed Timepoint Post First Dose of Study Medication
Baseline is FEV1 collected prior to first double-blind dose at week 0. Change is defined as Week 0 FEV1 percent predicted - Week 2 pre first dose FEV1 percent predicted.
Time frame: 2 weeks
Peak Change in FEV1 Over 12 Hours Post Dose From Study Baseline
12 hour peak change in FEV1 is defined as maximum of the post dose changes through the nominal 12 hour assessment.
Time frame: 2 weeks
Time to Onset in Participants Who Achieved a 10% Increase in FEV1 From Visit Predose After 2 Weeks
Analyzed from end of dosing to 12 hours.
Time frame: 2 weeks
Time to Onset in Participants Who Achieved a 15% Increase in FEV1 From Visit Predose After 2 Weeks
Analyzed from end of dosing to 12 hours.
Time frame: 2 weeks
Change in Inspiratory Capacity From Study Baseline to the 24 Hour Timepoint (Trough) Following 2 Weeks of Dosing
Trough Inspiratory Capacity is defined as the measurement collected approximately 24 hours after the first in clinic double-blind treatment dose at week 0. Change is calculated as Week 2 24 hr post dose IC - Week 0 pre first dose IC.
Time frame: 2 weeks
Change in Forced Vital Capacity (FVC) From Study Baseline at Each Assessed Post Dose Timepoint
Time frame: 2 Weeks
Levalbuterol Metered Dose Inhaler (MDI) (Rescue Medication) Use in Days Per Week
Overall: Average of the levalbuterol usage in days per week over the 2 week period. Mean number of days/week=number of days levalbuterol used during time period, divided by number of days in the period, multiplied by 7. An actuation is one puff of levalbuterol.
Time frame: 2 weeks
Levalbuterol Metered Dose Inhaler (MDI) Rescue Medication Use in Actuations Per Day
Overall: Average of the usage in number of actuations per day over the 2 week period. An actuation is one puff of levalbuterol. Mean number of actuations/day=number actuations used during time period, divided by number of days in time period.
Time frame: 2 weeks
Transition Dyspnea Index (TDI) Focal Score
TDI Focal score (range -9 to 9) is defined as the sum of function impairment, magnitude of task, and magnitude of effort (each on a -3 to 3 scale). A score of -9 is maximum worsening and 9 is maximum improvement.
Time frame: 2 weeks
Number of Participants With a >= 1 Unit of Improvement in the TDI Focal Score
A Greater than or Equal to 1 unit of Improvement in the TDI Focal Score is considered to be clinically important.
Time frame: 2 weeks
Percentage of Participants With a >=1 Unit Improvement in Transition Dysnea Index (TDI) Focal Score
A Greater than or Equal to 1 unit of Improvement in the TDI Focal Score is considered to be clinically important.
Time frame: 2 weeks
Multicenter (34 sites) study.
| Milestone | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Started | 76 | 80 | 78 |
| Completed | 71 | 76 | 74 |
| Not completed | 5 | 4 | 4 |
| Withdrew: Adverse event | 2 | 1 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Noncompliance with study requirements | 2 | 1 | 2 |
| Liters | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Time-normalized Area Under the Change From Study Baseline Curve for Forced Expiratory Volume in One Second (FEV1) Over 24 Hours (nAUC0-24B) | 0.104 (0.054 to 0.155) | 0.080 (0.035 to 0.124) | 0.221 (0.175 to 0.267) |
| Liters | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Time-normalized Area From Study Baseline Curve for FEV1 Over 0-12 Hours (nAUC0-12B) | 0.118 (0.070 to 0.167) | 0.130 (0.084 to 0.177) | 0.242 (0.195 to 0.290) |
| Liters | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Time Normalized Area Under the Change From Study Baseline Curve for FEV1 Over 12-24 Hours (nAUC12-24B) | 0.094 (0.036 to 0.151) | 0.054 (0.008 to 0.101) | 0.217 (0.169 to 0.264) |
Trough FEV1 is defined as the measurement collected approximately 24 hours after the first in-clinic double-blind dose at Week 0. Change is calculated as Week 2 24 hour post first dose FEV1 - Week 0 pre-first dose FEV1.
| Liters | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Change in FEV1 From Study Baseline to the 24-hour Timepoint (Trough) | 0.086 (0.031 to 0.141) | 0.080 (0.032 to 0.129) | 0.154 (0.103 to 0.206) |
Baseline is FEV1 measurement collected prior to the first double-blind dose at week 0. Change defined as Week 0 FEV1 - Week 2 pre first dose FEV1.
| Liters | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Week 0: immediately post first dose; N=76, 78, 78 | 0.132 ± 0.155 | -0.20 ± 0.084 | 0.139 ± 0.151 |
| Week 0: 30 minutes post first dose; N=75, 78, 76 | 0.163 ± 0.137 | 0.056 ± 0.093 | 0.183 ± 0.152 |
| Week 0: 1 hour post first dose; N=75, 78, 77 | 0.182 ± 0.150 | 0.106 ± 0.141 | 0.189 ± 0.161 |
| Week 0: 2 hours post first dose; N=76, 78, 77 | 0.193 ± 0.156 | 0.140 ± 0.148 | 0.239 ± 0.170 |
| Week 0: 4 hours post first dose; N=75, 77, 77 | 0.155 ± 0.169 | 0.120 ± 0.169 | 0.223 ± 0.189 |
| Week 0: 6 hours post first dose; N=72, 74, 77 | 0.128 ± 0.156 | 0.125 ± 0.188 | 0.214 ± 0.184 |
| Week 0: 8 hours post first dose; N=70, 73, 77 | 0.102 ± 0.183 | 0.109 ± 0.208 | 0.194 ± 0.180 |
| Week 0: 10 hours post first dose; N=69, 71, 76 | 0.101 ± 0.150 | 0.111 ± 0.184 | 0.190 ± 0.176 |
| Week 0: 12 hours post first dose; N=69, 71, 75 | 0.044 ± 0.181 | 0.094 ± 0.196 | 0.199 ± 0.202 |
| Week 2: immediately post first dose; N=71, 75, 74 | 0.154 ± 0.207 | 0.066 ± 0.184 | 0.240 ± 0.206 |
| Week 2: 30 minutes post first dose; N=70, 74, 74 | 0.188 ± 0.222 | 0.126 ± 0.200 | 0.280 ± 0.216 |
| Week 2: 1 hour post first dose; N=71, 75, 73 | 0.185 ± 0.222 | 0.163 ± 0.251 | 0.308 ± 0.232 |
| Week 2: 2 hours post first dose; N=71, 73, 74 | 0.213 ± 0.226 | 0.195 ± 0.248 | 0.330 ± 0.228 |
| Week 2: 4 hours post first dose; N=69, 72, 74 | 0.154 ± 0.227 | 0.164 ± 0.250 | 0.279 ± 0.239 |
| Week 2: 6 hours post first dose; N=69, 72, 73 | 0.123 ± 0.211 | 0.143 ± 0.226 | 0.266 ± 0.208 |
| Week 2: 8 hours post first dose; N=69, 70, 74 | 0.067 ± 0.221 | 0.138 ± 0.233 | 0.220 ± 0.215 |
| Week 2: 10 hours post first dose; N=69, 71, 71 | 0.054 ± 0.224 | 0.109 ± 0.179 | 0.205 ± 0.211 |
| Week 2: 12 hours post first dose; N=63, 67, 71 | 0.035 ± 0.211 | 0.101 ± 0.204 | 0.189 ± 0.210 |
| Week 2: immediately post second dose; N=65, 67, 72 | 0.115 ± 0.223 | 0.040 ± 0.215 | 0.235 ± 0.202 |
| Week 2: 12.5 hours post first dose; N=65, 66, 72 | 0.143 ± 0.235 | 0.063 ± 0.213 | 0.270 ± 0.214 |
| Week 2: 13 hours post first dose; N=63, 68, 72 | 0.159 ± 0.234 | 0.061 ± 0.196 | 0.272 ± 0.220 |
| Week 2: 14 hours post first dose; N=65, 71, 72 | 0.182 ± 0.248 | 0.068 ± 0.221 | 0.292 ± 0.234 |
| Week 2: 16 hours post first dose; N=63, 70, 71 | 0.114 ± 0.233 | 0.048 ± 0.239 | 0.240 ± 0.216 |
| Week 2: 23 hours post first dose; N=70, 74, 74 | 0.040 ± 0.236 | -0.006 ± 0.212 | 0.145 ± 0.208 |
| Week 2: 24 hours post first dose; N=69, 73, 74 | 0.086 ± 0.229 | 0.080 ± 0.207 | 0.154 ± 0.223 |
Baseline is FEV1 collected prior to first double-blind dose at week 0. Change is defined as Week 0 FEV1 percent predicted - Week 2 pre first dose FEV1 percent predicted.
| Percent of predicted FEV1 | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Week 0: Immediately post first dose; N=76, 78, 78 | 4.3 ± 4.6 | -0.6 ± 2.5 | 4.7 ± 4.9 |
| Week 0: 30 minutes post first dose; N=75, 78, 76 | 5.5 ± 4.4 | 2.0 ± 3.2 | 6.1 ± 5.2 |
| Week 0: 1 hour post first dose; N-75, 78, 77 | 6.1 ± 4.8 | 3.5 ± 4.6 | 6.3 ± 5.4 |
| Week 0: 2 hours post first dose; N=76, 78, 77 | 6.6 ± 5.0 | 4.7 ± 5.1 | 8.1 ± 5.7 |
| Week 0: 4 hours post first dose; N=75, 77, 77 | 5.3 ± 5.5 | 4.0 ± 5.3 | 7.5 ± 6.3 |
| Week 0: 6 hours post first dose; N=72, 74, 77 | 4.4 ± 5.0 | 4.1 ± 5.9 | 7.3 ± 6.3 |
| Week 0: 8 hours post first dose; N=70, 73, 77 | 3.5 ± 5.5 | 3.5 ± 6.5 | 6.6 ± 6.2 |
| Week 0: 10 hours post first dose; N=69, 71, 76 | 3.3 ± 4.6 | 3.7 ± 5.6 | 6.5 ± 5.9 |
| Week 0: 12 hours post first dose; N=69, 71, 75 | 1.6 ± 6.0 | 2.9 ± 6.1 | 6.7 ± 6.6 |
| Week 2: Immediately post first dose; N=71, 75, 74 | 5.1 ± 6.4 | 1.9 ± 5.9 | 8.0 ± 6.7 |
| Week 2: 30 minutes post first dose; N=70, 74, 74 | 6.2 ± 7.0 | 4.0 ± 6.3 | 9.3 ± 6.9 |
| Week 2: 1 hour post first dose; N=71, 75, 73 | 6.2 ± 7.1 | 5.2 ± 7.6 | 10.2 ± 7.3 |
| Week 2: 2 hours post first dose; N=71, 73, 74 | 7.1 ± 7.1 | 6.3 ± 7.3 | 11.0 ± 7.4 |
| Week 2: 4 hours post first dose; N=69, 72, 74 | 5.1 ± 7.4 | 5.1 ± 7.5 | 9.2 ± 7.6 |
| Week 2: 6 hours post first dose; N=69, 72, 73 | 4.0 ± 6.3 | 4.7 ± 6.9 | 8.8 ± 6.6 |
| Week 2: 8 hours post first dose; N=69, 70, 74 | 2.0 ± 7.0 | 4.4 ± 7.1 | 7.4 ± 6.9 |
| Week 2: 10 hours post first dose; N=69, 71, 71 | 1.8 ± 7.2 | 3.5 ± 5.7 | 6.8 ± 6.8 |
| Week 2: 12 hours post first dose; N=63, 67, 71 | 1.3 ± 6.7 | 3.4 ± 6.3 | 6.3 ± 6.9 |
| Week 2: Immediately post second dose; N=65, 67, 72 | 3.8 ± 6.9 | 1.1 ± 6.8 | 7.8 ± 6.6 |
| Week 2: 12.5 hours post first dose; N=65, 66, 72 | 4.9 ± 7.2 | 2.0 ± 6.5 | 9.0 ± 7.0 |
| Week 2: 13 hours post first dose; N=63, 68, 72 | 5.4 ± 7.3 | 1.8 ± 6.0 | 9.1 ± 7.1 |
| Week 2: 14 hours post first dose; N=65, 71, 72 | 6.0 ± 7.6 | 2.0 ± 6.7 | 9.8 ± 7.7 |
| Week 2: 16 hours post first dose; N=63, 70, 71 | 3.9 ± 7.1 | 1.4 ± 7.3 | 8.0 ± 6.9 |
| Week 2: 23 hours post first dose; N=70, 74, 74 | 1.3 ± 7.0 | -0.2 ± 6.5 | 4.8 ± 6.7 |
| Week 2: 24 hours post first dose; N=69, 73, 74 | 2.8 ± 6.9 | 2.6 ± 6.6 | 5.2 ± 7.2 |
12 hour peak change in FEV1 is defined as maximum of the post dose changes through the nominal 12 hour assessment.
| Liters | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Week 0; N=76, 79, 78 | 0.264 (0.231 to 0.296) | 0.218 (0.179 to 0.257) | 0.311 (0.272 to 0.350) |
| Week 2; N=71, 75, 74 | 0.273 (0.223 to 0.324) | 0.265 (0.212 to 0.319) | 0.379 (0.328 to 0.430) |
Analyzed from end of dosing to 12 hours.
| Hours | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Time to Onset in Participants Who Achieved a 10% Increase in FEV1 From Visit Predose After 2 Weeks | 0.39 (0.02 to 7.03) | 0.72 (0.02 to 10.07) | 0.17 (0.03 to 6.80) |
Analyzed from end of dosing to 12 hours.
| Hours | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Time to Onset in Participants Who Achieved a 15% Increase in FEV1 From Visit Predose After 2 Weeks | 0.76 (0.02 to 7.90) | 1.29 (0.03 to 7.25) | 0.39 (0.08 to 10.88) |
Trough Inspiratory Capacity is defined as the measurement collected approximately 24 hours after the first in clinic double-blind treatment dose at week 0. Change is calculated as Week 2 24 hr post dose IC - Week 0 pre first dose IC.
| Liters | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Change in Inspiratory Capacity From Study Baseline to the 24 Hour Timepoint (Trough) Following 2 Weeks of Dosing | 0.074 (0.00 to 0.147) | 0.023 (-0.047 to 0.094) | 0.150 (0.065 to 0.235) |
| Liters | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Week 0: Immediately post first dose; N=76, 78, 78 | 0.276 ± 0.270 | -0.031 ± 0.165 | 0.259 ± 0.305 |
| Week 0: 30 minutes post first dose; N=75, 78, 76 | 0.312 ± 0.267 | 0.122 ± 0.210 | 0.323 ± 0.347 |
| Week 0: 1 hour post first dose; N=75, 78, 77 | 0.344 ± 0.275 | 0.197 ± 0.283 | 0.351 ± 0.348 |
| Week 0: 2 hours post first dose; N=76, 78, 77 | 0.376 ± 0.319 | 0.248 ± 0.279 | 0.429 ± 0.366 |
| Week 0: 4 hours post first dose; N=75, 77, 77 | 0.291 ± 0.341 | 0.206 ± 0.293 | 0.392 ± 0.375 |
| Week 0: 6 hours post first dose; N=72, 74, 77 | 0.242 ± 0.303 | 0.195 ± 0.327 | 0.371 ± 0.352 |
| Week 0: 8 hours post first dose; N=70, 73, 77 | 0.207 ± 0.334 | 0.159 ± 0.360 | 0.338 ± 0.325 |
| Week 0: 10 hours post first dose; N=69, 71, 76 | 0.209 ± 0.267 | 0.175 ± 0.311 | 0.346 ± 0.357 |
| Week 0: 12 hours post first dose; N=69, 71, 75 | 0.131 ± 0.299 | 0.146 ± 0.325 | 0.344 ± 0.352 |
| Week 2: Immediately post first dose; N=71, 75, 74 | 0.293 ± 0.368 | 0.055 ± 0.301 | 0.389 ± 0.392 |
| Week 2: 30 minutes post first dose; N=70, 74, 74 | 0.343 ± 0.381 | 0.203 ± 0.350 | 0.461 ± 0.425 |
| Week 2: 1 hour post first dose; N=71, 75, 73 | 0.350 ± 0.397 | 0.224 ± 0.408 | 0.487 ± 0.426 |
| Week 2: 2 hours post first dose; N=71, 73, 74 | 0.380 ± 0.389 | 0.290 ± 0.387 | 0.526 ± 0.426 |
| Week 2: 4 hours post first dose; N=69, 72, 74 | 0.265 ± 0.342 | 0.221 ± 0.372 | 0.461 ± 0.441 |
| Week 2: 6 hours post first dose; N=69, 72, 73 | 0.202 ± 0.322 | 0.209 ± 0.356 | 0.413 ± 0.383 |
| Week 2: 8 hours post first dose; N=69, 70, 74 | 0.136 ± 0.347 | 0.214 ± 0.319 | 0.349 ± 0.387 |
| Week 2: 10 hours post first dose; N=69, 71, 71 | 0.098 ± 0.364 | 0.158 ± 0.278 | 0.323 ± 0.379 |
| Week 2: 12 hours post first dose; N=63, 67, 71 | 0.087 ± 0.340 | 0.124 ± 0.365 | 0.301 ± 0.398 |
| Week 2: Immediately post second dose; N=65, 67, 72 | 0.210 ± 0.397 | 0.034 ± 0.356 | 0.360 ± 0.385 |
| Week 2: 12.5 hours post first dose; N=65, 66, 72 | 0.262 ± 0.416 | 0.087 ± 0.359 | 0.399 ± 0.407 |
| Week 2: 13 hours post first dose; N=63, 68, 72 | 0.307 ± 0.376 | 0.082 ± 0.329 | 0.424 ± 0.432 |
| Week 2: 14 hours post first dose; N=65, 71, 72 | 0.343 ± 0.386 | 0.110 ± 0.342 | 0.459 ± 0.445 |
| Week 2: 16 hours post first dose; N=63, 70, 71 | 0.215 ± 0.374 | 0.098 ± 0.361 | 0.374 ± 0.422 |
| Week 2: 23 hours post first dose; N=70, 74, 74 | 0.082 ± 0.363 | -0.011 ± 0.340 | 0.226 ± 0.345 |
| Week 2: 24 hours post first dose; N=69, 73, 74 | 0.138 ± 0.365 | 0.115 ± 0.335 | 0.250 ± 0.408 |
Overall: Average of the levalbuterol usage in days per week over the 2 week period. Mean number of days/week=number of days levalbuterol used during time period, divided by number of days in the period, multiplied by 7. An actuation is one puff of levalbuterol.
| Days per week | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Baseline: Number of days used per week | 4.44 (3.79 to 5.08) | 4.27 (3.61 to 4.92) | 4.57 (3.94 to 5.20) |
| Overall: Number of days used per week | 2.16 (1.57 to 2.75) | 1.94 (1.40 to 2.47) | 1.38 (0.87 to 1.89) |
Overall: Average of the usage in number of actuations per day over the 2 week period. An actuation is one puff of levalbuterol. Mean number of actuations/day=number actuations used during time period, divided by number of days in time period.
| Actuations per day | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Baseline: Number of actuations per day | 3.24 (2.50 to 3.98) | 2.77 (2.16 to 3.39) | 3.08 (2.47 to 3.69) |
| Overall: Number of actuations per day | 1.18 (0.75 to 1.61) | 1.00 (0.59 to 1.40) | 0.68 (0.36 to 1.00) |
TDI Focal score (range -9 to 9) is defined as the sum of function impairment, magnitude of task, and magnitude of effort (each on a -3 to 3 scale). A score of -9 is maximum worsening and 9 is maximum improvement.
| Units on a scale | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Transition Dyspnea Index (TDI) Focal Score | 2.28 ± 2.39 | 1.79 ± 2.83 | 3.13 ± 2.44 |
A Greater than or Equal to 1 unit of Improvement in the TDI Focal Score is considered to be clinically important.
| Participants | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Number of Participants With a >= 1 Unit of Improvement in the TDI Focal Score | 50 | 44 | 60 |
A Greater than or Equal to 1 unit of Improvement in the TDI Focal Score is considered to be clinically important.
| Percentage of participants | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Percentage of Participants With a >=1 Unit Improvement in Transition Dysnea Index (TDI) Focal Score | 66.67 | 57.14 | 77.92 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arformoterol 15 Mcg Twice Daily | — | — | — |
| Tiotropium 18 Mcg Once Daily | — | — | — |
| Arformoterol /Tiotropium | — | — | — |
| Event | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| Small Intestinal ObstructionGastrointestinal disorders | 1/76 | 0/80 | 0/78 |
| Event | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium |
|---|---|---|---|
| HeadacheNervous system disorders | 1/76 | 3/80 | 4/78 |
| BronchitisInfections and infestations | 2/76 | 0/80 | 0/78 |
| Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders | 2/76 | 1/80 | 2/78 |
| DiarrhoeaGastrointestinal disorders | 0/76 | 0/80 | 2/78 |
| Chest PainGeneral disorders | 0/76 | 0/80 | 2/78 |
| DizzinessNervous system disorders | 1/76 | 1/80 | 2/78 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/76 | 2/80 | 2/78 |
| HypertensionVascular disorders | 0/76 | 2/80 | 2/78 |
| NauseaGastrointestinal disorders | 1/76 | 2/80 | 0/78 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 0/76 | 2/80 | 0/78 |
| Age, Categorical(Participants) | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 47 | 50 | 52 | 149 |
| >=65 years | 29 | 30 | 26 | 85 |
| Age Continuous(years) | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium | Total |
|---|---|---|---|---|
| Mean | 61.6 ± 8.4 | 61.2 ± 9.5 | 62.2 ± 7.6 | 61.7 ± 8.5 |
| Sex: Female, Male(Participants) | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium | Total |
|---|---|---|---|---|
| Female | 37 | 37 | 36 | 110 |
| Male | 39 | 43 | 42 | 124 |
| Race (NIH/OMB)(Participants) | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 6 | 7 | 18 |
| White | 71 | 74 | 70 | 215 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium | Total |
|---|---|---|---|---|
| United States | 76 | 80 | 78 | 234 |
| Number of Pack Years Smoked(Participants) | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium | Total |
|---|---|---|---|---|
| >=15 years to <25 years | 0 | 1 | 6 | 7 |
| >=25 years to <=30 years | 4 | 4 | 4 | 12 |
| >=30 years | 72 | 75 | 68 | 215 |
| Packs per day currently smoked(Participants) | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium | Total |
|---|---|---|---|---|
| >0 to 1 pack | 24 | 30 | 22 | 76 |
| >1 to 2 packs | 22 | 24 | 16 | 62 |
| >2 to 4 packs | 3 | 0 | 1 | 4 |
| >4 packs | 0 | 0 | 0 | 0 |
| Currently does not smoke | 27 | 26 | 39 | 92 |
| Baseline Dyspnea Index (BDI) Focal Score(units on a scale) | Arformoterol 15 Mcg Twice Daily | Tiotropium 18 Mcg Once Daily | Arformoterol /Tiotropium | Total |
|---|---|---|---|---|
| Mean | 5.8 ± 2.0 | 5.8 ± 1.9 | 5.5 ± 2.1 | 5.7 ± 2.0 |
5 further baseline measures are reported on the registry.
The record gives a start of Dec 2006, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2009, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Formoterol · Tiotropium
Pulmonary Disease, Chronic Obstructive →
Sumitomo Pharma America, Inc. →